Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Children's Hospital of Fudan University
Modality
Cell therapy
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
30Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02551003CT.gov Neuroprotective Effect of Autologous Cord Blood Combined With Therapeutic Hypothermia Following Neonatal Encephalopathy | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cerebral Infarction
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Autologous Umbilical Cord Blood (this asset) | Children's Hospital of Fudan University | P1/2 | CC · 43 |
| Cilostazol | Asan Medical Center | P4 | BBB |
| Aspirin | Sclnow Biotechnology Co., Ltd. | P4 | BBB |
| Sovateltide | Pharmazz, Inc. | P4 | BBB |
| Clopidogrel | The Second Hospital of Anhui Medical University | P4 | BBB |
| Human Urinary Kallidinogenase | Huisheng Chen | P4 | BB |
| Atorvastatin | Sclnow Biotechnology Co., Ltd. | P4 | BB |
| Tenecteplase | Second Affiliated Hospital, School of Medicine, Zhejiang University | P3 | BB |
| Hua Tuo Zai Zao Wan | Guangzhou University of Traditional Chinese Medicine | P4 | BB |
+41 more in the Cerebral Infarction cohort
Other indications for Autologous Umbilical Cord Blood
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Brain Hypoxia - Ischemia | — | P2 | CCC · 55 |
| Pediatric Arterial Ischemic Stroke | — | P1/2 | CC · 45 |
| Traumatic Brain Injury | — | P1/2 | CC · 41 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Autologous Umbilical Cord Blood in Cerebral Infarction. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/autologous-umbilical-cord-blood-cerebral-infarction
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →